3TC 150 MG — DIN 02192683
LAMIVUDINE : 150 MG · VIIV HEALTHCARE ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is 3TC?
3TC 150 MG contains LAMIVUDINE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02192683, held by VIIV HEALTHCARE ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 15-Nov-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is 3TC used for?
In combination with other antiretroviral agents for the treatment of HIV infection.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Lamivudine cost around the world?
Lamivudine is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Belgium publishes a public; Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 39 | 43 | ZAR███.██ |
| United States | acquisition | 3 | 13 | USD███.██ |
| Morocco | PPV (public price) | 4 | 10 | MAD███.██ |
| Saudi Arabia | public | 9 | 10 | SAR███.██ |
| Australia | ex-manufacturer | 6 | 9 | AUD███.██ |
| Hungary | producer price (ex-factory) | 6 | 6 | HUF███.██ |
| Greece | producer price (ex-factory) | 5 | 5 | EUR███.██ |
| United Arab Emirates | public | 2 | 2 | AED███.██ |
| Belgium | public | 2 | 2 | EUR███.██ |
100 pack listings across 76 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Lamivudine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Lamivudine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Lamivudine, across 14 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 3 | 3 | APO-LAMIVUDINE, APO-LAMIVUDINE HBV | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 3 | 3 | JAMP LAMIVUDINE, JAMP LAMIVUDINE HBV | Sourceable in Canada |
| VIIV HEALTHCARE ULC | 3 | 3 | 3TC | Sourceable in Canada |
| AURO PHARMA INC | 2 | 0 | AURO-LAMIVUDINE | No marketed DIN |
| GLAXOSMITHKLINE INC | 2 | 0 | HEPTOVIR | No marketed DIN |
| AUROBINDO PHARMA LIMITED (UNIT III) | 1 | 0 | LAMIVUDINE ORAL SOLUTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 150 mg tablets: Bottles of 60; 300 mg tablets: Bottles of 30; Oral solution: 240 mL plastic bottles. |
| Storage | Not explicitly detailed in provided text (section 11 referenced but content not shown), though standard room temperature is typical for these forms. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Lamivudine |
|---|---|
| ATC code | J05AF05 |
| AHFS class | 08:18.08.20 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02192683 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2192683 |
| Brand name | 3TC |
| Generic / active ingredient | LAMIVUDINE : 150 MG |
| Market authorization holder | VIIV HEALTHCARE ULC |
| Health Canada schedule | Prescription |
| ATC code | J05AF05 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AF |
| Current status | MARKETED |
| Status date | 15-Nov-2013 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults/Adolescents (≥25 kg): 300 mg daily (150 mg BID or 300 mg QD). Pediatrics (≥3 months): 5 mg/kg BID or 10 mg/kg QD. Can be taken with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to lamivudine or any components of the product.
Warnings and precautions
Post-treatment exacerbations of Hepatitis B; Pancreatitis (especially in pediatrics); Lactic acidosis and severe hepatomegaly with steatosis; Immune Reconstitution Inflammatory Syndrome.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 14 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| 3TC | 300 MG | TABLET | VIIV HEALTHCARE ULC | MARKETED | 02247825 |
| 3TC | 10 MG | SOLUTION | VIIV HEALTHCARE ULC | MARKETED | 02192691 |
| APO-LAMIVUDINE | 300 MG | TABLET | APOTEX INC | MARKETED | 02369060 |
| APO-LAMIVUDINE | 150 MG | TABLET | APOTEX INC | MARKETED | 02369052 |
| APO-LAMIVUDINE HBV | 100 MG | TABLET | APOTEX INC | MARKETED | 02393239 |
| JAMP LAMIVUDINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02507110 |
| JAMP LAMIVUDINE | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02507129 |
| JAMP LAMIVUDINE HBV | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02512467 |
| AURO-LAMIVUDINE | 300 MG | TABLET | AURO PHARMA INC | CANCELLED POST MARKET | 02410567 |
| AURO-LAMIVUDINE | 150 MG | TABLET | AURO PHARMA INC | CANCELLED POST MARKET | 02410575 |
2 · Same class — other molecules in ATC J05AF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tenofovir Disoproxil | AG-TENOFOVIR · APO-TENOFOVIR · AURO-TENOFOVIR · JAMP-TENOFOVIR · +8 more | 13 | 13 | Yes |
| Entecavir | ACCEL-ENTECAVIR · APO-ENTECAVIR · AURO-ENTECAVIR · BARACLUDE · +6 more | 12 | 10 | Yes |
| Lamivudine | 3TC · APO-LAMIVUDINE · APO-LAMIVUDINE HBV · AURO-LAMIVUDINE · +4 more | 14 | 9 | Yes |
| Zidovudine | APO-ZIDOVUDINE · NOVO-AZT CAP 100MG · RETROVIR (AZT) · RETROVIR (AZT) 300MG · +1 more | 7 | 3 | Yes |
| Abacavir | APO-ABACAVIR · MINT-ABACAVIR · ZIAGEN | 4 | 3 | Yes |
| Tenofovir Alafenamide | VEMLIDY | 1 | 1 | Yes |
| Didanosine | VIDEX CHEWABLE DISPERSIBLE TAB 100MG · VIDEX CHEWABLE DISPERSIBLE TAB 150MG · VIDEX CHEWABLE DISPERSIBLE TAB 25MG · VIDEX CHEWABLE DISPERSIBLE TAB 50MG · +2 more | 9 | 0 | Not in Canada |
| Stavudine | ZERIT · ZERIT - CAP 15MG · ZERIT - CAP 20MG · ZERIT - CAP 30MG · +1 more | 5 | 0 | Not in Canada |
| Zalcitabine | HIVID TAB 0.375MG · HIVID TAB 0.75 MG | 2 | 0 | Not in Canada |
| Adefovir Dipivoxil | AA-ADEFOVIR · HEPSERA | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is 3TC called?
The same molecule, Lamivudine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Zeffix | Latin | Australia, Morocco, Saudi Arabia |
| LAMIVIR | Latin | Morocco |
| AVOLAM | Latin | Morocco |
| Cipla Lamivudine Oral Solution | Latin | South Africa |
| Combivir | Latin | Australia, South Africa |
| EPIVIR | Latin | Morocco |
| Lamivudine Viatris | Latin | Australia |
| Mivuten | Latin | South Africa |
| Adco-Lamivudine Solution | Latin | South Africa |
| Adco-Lamivudine Tablets | Latin | South Africa |
| Aspen Lamivudine Syrup | Latin | South Africa |
| Aspen Lamzid | Latin | South Africa |
| Cipla Lamivudine | Latin | South Africa |
| COMBIVIR F.C TAB | Latin | Saudi Arabia |
| Divuwin | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.